{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:03:12Z","timestamp":1788436992856,"version":"build-2803163510"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2023.101166","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T01:19:37Z","timestamp":1703985577000},"page":"101166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies"],"prefix":"10.1016","volume":"64","author":[{"given":"Azin","family":"Vakilpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Scherrer-Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1016\/j.blre.2023.101166_bb0010","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0015","first-page":"419","article-title":"Echocardiography imaging of cardiotoxicity","volume":"37","author":"Kang","year":"2019","journal-title":"Cardiol Clin"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy\u2013induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.blre.2023.101166_bb0025","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","article-title":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","volume":"65","author":"Barac","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2023.101166_bb0030","first-page":"339","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort","author":"Mulrooney","year":"2009","journal-title":"Bmj."},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0035","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0040","first-page":"54","article-title":"Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019","volume":"9","author":"Raisi-Estabragh","year":"2023","journal-title":"Eur Heart J-Qual Care Clin Outcomes"},{"issue":"7","key":"10.1016\/j.blre.2023.101166_bb0045","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-022-01596-z","article-title":"Changing causes of death in persons with haematological cancers 1975\u20132016","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0050","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14737140.2017.1344099","article-title":"Risk of cardiac death among cancer survivors in the United States: a SEER database analysis","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2023.101166_bb0055","series-title":"Mayo Clinic Proceedings","article-title":"Prevalence of preexisting cardiovascular disease in patients with different types of cancer: The unmet need for onco-cardiology","year":"2016"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cpcardiol.2008.01.002","article-title":"The diagnosis and management of cardiovascular disease in cancer patients","volume":"33","author":"Yusuf","year":"2008","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ncponc1225","article-title":"Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy","volume":"5","author":"Khakoo","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0070","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0085","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"22","key":"10.1016\/j.blre.2023.101166_bb0090","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.blre.2023.101166_bb0100","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2023.101166_bb0105","unstructured":"NCI Dictionary of Cancer Terms. Definition of cardiotoxicity. [Internet]. n.d. Available from: http:\/\/www.cancer.gov\/dictionary?CdrID=44004%3E."},{"issue":"27","key":"10.1016\/j.blre.2023.101166_bb0110","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas dermo-sifiliograf"},{"issue":"16","key":"10.1016\/j.blre.2023.101166_bb0125","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart."},{"issue":"41","key":"10.1016\/j.blre.2023.101166_bb0135","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ajcp\/100.2.158","article-title":"Myocarditis associated with doxorubicin cardiotoxicity","volume":"100","author":"Gaudin","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/clc.22634","article-title":"Short and long term radiation induced cardiovascular disease in patients with cancer","volume":"40","author":"Nielsen","year":"2017","journal-title":"Clin Cardiol"},{"issue":"23","key":"10.1016\/j.blre.2023.101166_bb0155","first-page":"3366","article-title":"Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.blre.2023.101166_bb0160","first-page":"481","article-title":"Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: an interim analysis","volume":"130","author":"Younes","year":"2017","journal-title":"Blood."},{"issue":"33","key":"10.1016\/j.blre.2023.101166_bb0165","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101166_bb0175","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2019-122896","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0185","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0190","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1002\/ajh.26043","article-title":"A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia","volume":"96","author":"Zheng","year":"2021","journal-title":"Am J Hematol"},{"issue":"42","key":"10.1016\/j.blre.2023.101166_bb0195","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.blre.2023.101166_bb0200","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2023.101166_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"24","key":"10.1016\/j.blre.2023.101166_bb0210","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.blre.2023.101166_bb0215","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.blre.2023.101166_bb0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","article-title":"Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients","volume":"142","author":"Willeit","year":"2020","journal-title":"Circulation."},{"issue":"18","key":"10.1016\/j.blre.2023.101166_bb0225","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/eurheartj\/ehy806","article-title":"Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina","volume":"40","author":"Reeh","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2023.101166_bb0230","article-title":"Evaluation of the EndoPAT as a tool to assess endothelial function","volume":"2012","author":"Moerland","year":"2012","journal-title":"J Vasc Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0235","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","article-title":"ESVM guidelines-the diagnosis and management of Raynaud\u2019s phenomenon","volume":"46","author":"Belch","year":"2017","journal-title":"Vasa."},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0240","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0250","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"61","author":"O\u2019gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.blre.2023.101166_bb0260","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0265","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.blre.2023.101166_bb0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2017.08.068","article-title":"International standardization of diagnostic criteria for microvascular angina","volume":"250","author":"Ong","year":"2018","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0275","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"24","key":"10.1016\/j.blre.2023.101166_bb0280","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2023.101166_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1225-6","article-title":"Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management","volume":"21","author":"Ala","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0290","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with Enasidenib, a selective inhibitor of mutant Isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.blre.2023.101166_bb0295","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a US Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0300","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/jcm9103342","article-title":"Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: a systematic review of the literature","volume":"9","author":"Gasparovic","year":"2020","journal-title":"J Clin Med"},{"issue":"19","key":"10.1016\/j.blre.2023.101166_bb0305","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0310","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J\u2013Cardiovasc Imag"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0315","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.5603\/KP.2015.0228","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases","volume":"73","author":"Adler","year":"2015","journal-title":"Kardiol Polska (Polish Heart J)"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0320","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.echo.2009.08.006","article-title":"Radiotherapy-induced mitral stenosis: a three-dimensional perspective","volume":"23","author":"Malanca","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0325","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0330","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"issue":"40","key":"10.1016\/j.blre.2023.101166_bb0335","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0340","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/europace\/euab232","volume":"24","author":"Glikson","year":"2022","journal-title":"EP Europace"},{"key":"10.1016\/j.blre.2023.101166_bb0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs","volume":"63","author":"Coppola","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2023.101166_bb0355","unstructured":"Vasbinder A, Hoeger Christopher W, Catalan T, Anderson E, Chu C, Kotzin M, et al. Cardiovascular events after hematopoietic stem cell transplant: Incidence and risk factors. JACC: CardioOncol. n.d. 0(0)."},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0360","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC: Clin Electrophysiol"},{"issue":"31","key":"10.1016\/j.blre.2023.101166_bb0365","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0370","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0375","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0380","first-page":"208","article-title":"Symptomatic heart failure in acute leukemia patients treated with anthracyclines","volume":"1","author":"Kang","year":"2019","journal-title":"Cardio Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0385","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcdd9080259","article-title":"Cardioprotective strategies from cardiotoxicity in cancer patients: a comprehensive review","volume":"9","author":"Kourek","year":"2022","journal-title":"J Cardiovasc Develop Disease"},{"key":"10.1016\/j.blre.2023.101166_bb0390","series-title":"Mayo Clinic Proceedings","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","year":"2014"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0395","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.blre.2015.11.001","article-title":"Maximizing anthracycline tolerability in hematologic malignancies: treat to each heart\u2019s content","volume":"30","author":"Oliveira","year":"2016","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0400","first-page":"250","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"Cardio Oncol"},{"key":"10.1016\/j.blre.2023.101166_bb0405","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.blre.2023.101166_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0415","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0420","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24608","article-title":"Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors","volume":"92","author":"Jouni","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0425","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0430","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101536","article-title":"Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy","volume":"48","author":"Zheng","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0440","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/eurjhf\/hft034","article-title":"Primary proteasome inhibition results in cardiac dysfunction","volume":"15","author":"Herrmann","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10.1016\/j.blre.2023.101166_bb0445","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0450","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood","volume":"5","author":"Atrash","year":"2015","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2023.101166_bb0455","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0460","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0465","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"haematologica."},{"issue":"13","key":"10.1016\/j.blre.2023.101166_bb0470","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"10.1016\/j.blre.2023.101166_bb0475","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0480","first-page":"570","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC: CardioOncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.blre.2023.101166_bb0490","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front Pharmacol"},{"issue":"35","key":"10.1016\/j.blre.2023.101166_bb0495","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0500","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0505","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101166_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and management of cardiotoxicity in hematologic malignancies","volume":"2021","author":"Bojan","year":"2021","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0515","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0520","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41409-021-01427-2","article-title":"Cardiac complications associated with hematopoietic stem-cell transplantation","volume":"56","author":"Ohmoto","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0525","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","article-title":"Late cardiovascular complications after hematopoietic cell transplantation","volume":"20","author":"Chow","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","article-title":"National institutes of health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report","volume":"23","author":"Armenian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0535","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cncr.28444","article-title":"Cardiovascular disease in survivors of hematopoietic cell transplantation","volume":"120","author":"Armenian","year":"2014","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0540","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41409-020-01080-1","article-title":"Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation","volume":"56","author":"Oliveira","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101166_bb0545","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2023.101166_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune checkpoint inhibitor toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.blre.2023.101166_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733890","article-title":"Toxicity of immune-checkpoint inhibitors in hematological malignancies","volume":"12","author":"Hradska","year":"2021","journal-title":"Front Pharmacol"},{"issue":"01","key":"10.1016\/j.blre.2023.101166_bb0570","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cdtm.2019.02.004","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","author":"Upadhrasta","year":"2019","journal-title":"Chronic Diseas Transl Med"},{"issue":"25","key":"10.1016\/j.blre.2023.101166_bb0575","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0580","first-page":"193","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"Cardio Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0585","first-page":"747","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: A prospective study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC: CardioOncol"},{"issue":"23","key":"10.1016\/j.blre.2023.101166_bb0590","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0595","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/0002-9149(83)90209-6","article-title":"Cardiac disease after radiation therapy for Hodgkin\u2019s disease: analysis of 48 patients","volume":"51","author":"Applefeld","year":"1983","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0600","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose-volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2023.101166_bb0605","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0610","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose\u2013volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0615","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.blre.2023.101166_bb0620","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann Hematol"},{"issue":"34","key":"10.1016\/j.blre.2023.101166_bb0625","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2023.101166_bb0630","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0635","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0640","first-page":"48","article-title":"Cardiovascular risk factors are associated with future cancer","volume":"3","author":"Lau","year":"2021","journal-title":"Cardio Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0645","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-019-0481-y","article-title":"Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK","volume":"121","author":"Plummer","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0650","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2023.101166_bb0655","article-title":"Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography","volume":"15","author":"Martinez","year":"2022","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0660","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study Group of the Heart Failure Association and the cardio-oncology Council of the European Society of cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0665","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0670","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0675","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0680","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"New Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2023.101166_bb0685","doi-asserted-by":"crossref","first-page":"32519","DOI":"10.18632\/oncotarget.8685","article-title":"Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: results from a randomized prospective clinical trial","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget."},{"issue":"18","key":"10.1016\/j.blre.2023.101166_bb0690","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"Lopez-Sendon","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2023.101166_bb0695","first-page":"8","article-title":"The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy: supplementary issue: biomarkers and their essential role in the development of personalised therapies (A)","author":"Henri","year":"2016","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.blre.2023.101166_bb0700","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","article-title":"Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults","volume":"97","author":"Dodos","year":"2008","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0705","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0710","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/annonc\/mdm499","article-title":"Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation","volume":"18","author":"Horacek","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0720","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur Heart J-Cardiovasc Imag"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0725","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy","volume":"16","author":"Negishi","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0730","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0735-1097(92)90138-D","article-title":"Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans","volume":"20","author":"Stoddard","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0735","first-page":"1","article-title":"BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and\/or Trastuzumab","volume":"3","author":"Dobson","year":"2021","journal-title":"JACC: CardioOncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0740","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/ehjci\/jead092","article-title":"Cardiac magnetic resonance imaging of pericardial diseases: a comprehensive guide","volume":"24","author":"Antonopoulos","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0745","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.echo.2013.12.005","article-title":"Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography","volume":"27","author":"Hoffmann","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0750","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ehjci\/jeu313","article-title":"Accuracy of cardiac CT, radionucleotide and invasive ventriculography, two-and three-dimensional echocardiography, and SPECT for left and right ventricular ejection fraction compared with cardiac MRI: a meta-analysis","volume":"16","author":"Pickett","year":"2015","journal-title":"Eur Heart J\u2013Cardiovasc Imag"},{"issue":"16","key":"10.1016\/j.blre.2023.101166_bb0755","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0760","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2007.06695.x","article-title":"Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions","volume":"138","author":"Chacko","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0765","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.12368","article-title":"Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients","volume":"162","author":"Pascal","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0770","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor\u2013Associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2023.101166_bb0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-019-0645-2","article-title":"Applications of cardiac computed tomography in the cardio-oncology population","volume":"20","author":"Layoun","year":"2019","journal-title":"Curr Treat Options in Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0780","first-page":"635","article-title":"Cardiac computed tomography in cardio-oncology","volume":"3","author":"Lopez-Mattei Juan","year":"2021","journal-title":"JACC: CardioOncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0785","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.117.191122","article-title":"Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational 18F-FDG PET\/CT observation","volume":"58","author":"Bauckneht","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0790","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0795","first-page":"19","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"Cardio Oncol"},{"issue":"20","key":"10.1016\/j.blre.2023.101166_bb0800","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0805","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer: Interdiscipl Intern J Am Cancer Soc"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0810","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA."},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0815","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0820","first-page":"68","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"Cardio Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0825","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","article-title":"Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes","volume":"523","author":"Yu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0830","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0835","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane\u00ae) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0840","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0845","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0850","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0855","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","article-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","volume":"200","author":"Oliveira","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0860","first-page":"54","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"Cardio Oncol"},{"issue":"23","key":"10.1016\/j.blre.2023.101166_bb0865","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0870","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.418","article-title":"Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers","volume":"8","author":"Henninger","year":"2018","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0875","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0880","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after Anthracycline- or Trastuzumab-Based chemotherapy for early breast cancer: a propensity score\u2013Matched cohort study","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb0885","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0890","first-page":"674","article-title":"The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy","volume":"5","author":"Onoue","year":"2023","journal-title":"JACC: CardioOncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101166_bb0895","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.freeradbiomed.2011.08.015","article-title":"Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system","volume":"51","author":"Asensio-L\u00f3pez","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104888","article-title":"Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study","volume":"9","author":"Kobashigawa","year":"2014","journal-title":"PLoS One"},{"issue":"Supplement_2","key":"10.1016\/j.blre.2023.101166_bb0905","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3253","article-title":"SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, leukotrienes\/interleukin 6 axis and mTORC1\/Fox01\/3a mediated apoptosis","volume":"41","author":"Quagliariello","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2023.101166_bb0910","first-page":"318","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC: CardioOncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101166_bb0915","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101166_bb0920","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0925","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41598-017-00075-1","article-title":"Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"7","author":"Leong","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0930","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2015.168","article-title":"Systems biology approaches to adverse drug effects: the example of cardio-oncology","volume":"12","author":"Brown","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0935","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2967\/jnumed.118.220137","article-title":"Precision cardio-oncology","volume":"60","author":"Dreyfuss","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.blre.2023.101166_bb0940","article-title":"Artificial intelligence and imaging: opportunities in cardio-oncology","volume":"15","author":"Madan","year":"2022","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"issue":"2","key":"10.1016\/j.blre.2023.101166_bb0945","first-page":"280","article-title":"Cancer therapy-related cardiac dysfunction of nonanthracycline chemotherapeutics","volume":"1","author":"Kamphuis Janine","year":"2019","journal-title":"JACC: CardioOncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101166_bb0950","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101166_bb0955","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","article-title":"Arrhythmias and other electrophysiology issues in Cancer patients receiving chemotherapy or radiation","volume":"18","author":"Viganego","year":"2016","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"10.1016\/j.blre.2023.101166_bb0960","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0965","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101166_bb0970","first-page":"1","article-title":"Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia","volume":"7","author":"Kim","year":"2021","journal-title":"Cardio-Oncol."},{"issue":"12","key":"10.1016\/j.blre.2023.101166_bb0975","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0980","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.blre.2023.101166_bb0985","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2023.101166_bb0990","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant Hemopathies","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2023.101166_bb0995","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101166_bb1000","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:32:33Z","timestamp":1759437153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":200,"alternative-id":["S0268960X23001364"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101166","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101166"}}